RÉSUMÉ
Each year, new drugs are introduced to the market, representing structures that have affinity for biological targets implicated in human diseases and conditions. These new chemical entities (NCEs), particularly small molecules and antibody-drug conjugates, provide insight into molecular recognition and serve as potential leads for the design of future medicines. This annual review is part of a continuing series highlighting the most likely process-scale synthetic approaches to 35 NCEs that were first approved anywhere in the world during 2021.
Sujet(s)
Conception de médicament , Humains , Préparations pharmaceutiques , Immunoconjugués/composition chimiqueRÉSUMÉ
New drugs introduced to the market are privileged structures that have affinities for biological targets implicated in human diseases and conditions. These new chemical entities (NCEs), particularly small molecules and antibody-drug conjugates (ADCs), provide insight into molecular recognition and simultaneously function as leads for the design of future medicines. This Review is part of a continuing series presenting the most likely process-scale synthetic approaches to 44 new chemical entities approved for the first time anywhere in the world during 2020.
Sujet(s)
Conception de médicament , Immunoconjugués , HumainsRÉSUMÉ
New drugs introduced to the market are privileged structures having affinities for biological targets implicated in human diseases and conditions. These new chemical entities (NCEs), particularly small molecules and antibody-drug conjugates, provide insight into molecular recognition and simultaneously function as leads for the design of future medicines. This review is part of a continuing series presenting the most likely process-scale synthetic approaches to 40 NCEs approved for the first time anywhere in the world in 2019.
Sujet(s)
Techniques de chimie synthétique/méthodes , Composés chimiques organiques/synthèse chimique , Préparations pharmaceutiques/synthèse chimique , Animaux , HumainsRÉSUMÉ
New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities (NCEs) provide insight into molecular recognition while serving as leads for designing future new drugs. This annual review describes the most likely process-scale synthetic approaches to 39 new chemical entities approved for the first time globally in 2018.
Sujet(s)
Agrément de médicaments , Préparations pharmaceutiques/composition chimique , Découverte de médicament , Histoire du 21ème siècle , Structure moléculaireRÉSUMÉ
New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities (NCEs) provide insight into molecular recognition while serving as leads for designing future new drugs. This annual review describes the most likely process-scale synthetic approaches to 31 new chemical entities approved for the first time globally in 2017.
Sujet(s)
Agrément de médicaments , Conception de médicament , Modèles chimiques , Préparations pharmaceutiques/synthèse chimique , Anti-infectieux/synthèse chimique , Anti-infectieux/composition chimique , Antinéoplasiques/synthèse chimique , Antinéoplasiques/composition chimique , Agents gastro-intestinaux/synthèse chimique , Agents gastro-intestinaux/composition chimique , Agents hématologiques/synthèse chimique , Agents hématologiques/composition chimique , Structure moléculaire , Solutions ophtalmiques/synthèse chimique , Solutions ophtalmiques/composition chimique , Préparations pharmaceutiques/composition chimique , Préparations pharmaceutiques/classificationRÉSUMÉ
New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities provide insight into molecular recognition while serving as leads for designing future new drugs. This annual review describes the most likely process-scale synthetic approaches to 19 new chemical entities that were approved for the first time in 2016.
Sujet(s)
Agrément de médicaments/histoire , Préparations pharmaceutiques/histoire , Conception de médicament , Histoire du 21ème siècle , Structure moléculaire , Préparations pharmaceutiques/synthèse chimique , Préparations pharmaceutiques/composition chimiqueRÉSUMÉ
New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities (NCEs) provide insight into molecular recognition while serving as leads for designing future new drugs. This annual review describes the most likely process-scale synthetic approaches to 29 new chemical entities (NCEs) that were approved for the first time in 2015.
Sujet(s)
Découverte de médicament/méthodes , Préparations pharmaceutiques/synthèse chimique , Anti-infectieux/synthèse chimique , Anti-inflammatoires non stéroïdiens/synthèse chimique , Antinéoplasiques/synthèse chimique , Agents cardiovasculaires/synthèse chimique , Agents du système nerveux central/synthèse chimique , Techniques de chimie synthétique , Agents gastro-intestinaux/synthèse chimique , Hypoglycémiants/synthèse chimique , Récepteurs à la thrombopoïétine/agonistesRÉSUMÉ
New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities (NCEs) provide insight into molecular recognition and also serve as leads for designing future new drugs. This annual review covers the synthesis of thirty-seven NCEs that were approved for the first time in 2014 and one drug which was approved in 2013 and was not covered in a previous edition of this review.
Sujet(s)
Conception de médicament , Commerce , Industrie pharmaceutiqueRÉSUMÉ
New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities (NCEs) provide insight into molecular recognition and also serve as leads for designing future new drugs. This annual review covers the synthesis of twenty-four NCEs that were approved for the first time in 2013 and two 2012 drugs which were not covered during the previous edition of this review.
Sujet(s)
Préparations pharmaceutiques/synthèse chimique , Conception de médicament , Structure moléculaire , Préparations pharmaceutiques/composition chimiqueRÉSUMÉ
New drugs introduced to the market every year represent a privileged structure for a particular biological target. These new chemical entities (NCEs) provide insights into molecular recognition and also serve as leads for designing future new drugs. This review covers the synthesis of twenty-six NCEs that were launched or approved worldwide in 2012 and two additional drugs which were launched at the end of 2011.
Sujet(s)
Préparations pharmaceutiques/synthèse chimique , Structure moléculaire , Préparations pharmaceutiques/composition chimiqueRÉSUMÉ
New drugs are introduced to the market every year and each represents a privileged structure for its biological target. These new chemical entities (NCEs) provide insights into molecular recognition and also serve as leads for designing future new drugs. This review covers the synthesis of 26 NCEs that were launched in the world in 2011.
Sujet(s)
Agrément de médicaments , Conception de médicament , Préparations pharmaceutiques/synthèse chimique , HumainsRÉSUMÉ
New drugs are introduced to the market every year and each represents a privileged structure for its biological target. These new chemical entities (NCEs) provide insights into molecular recognition and also serve as leads for designing future new drugs. This review covers the synthesis of 15 NCEs that were launched anywhere in the world in 2010.